Posted in | News | Renewable Energy | Wind Power

Testing of Wind Augmenter and Wind Diverter Commences in Mass Megawatts Wind Power’s Hunter Project

The Hunter Project of Mass Megawatts Wind Power has been considerably completed and testing of the new wind augmenter and wind diverter has commenced. This project will be operational after the completion of the initial testing of the new technologies and testing of the furling system. The wind velocity is increased to more than 50% by the wind augmenter resulting in a 3-fold increase in the production of energy. This increase is highlighted in the initial test results. The wind diverter also brings about an additional increase of 100% more power output from the blades.

New technology in Mass Megawatts’ MAT (Multiaxis Turbosysyem) helps to improve the wind speed while reducing vertical height, thus reducing steel costs. This promotes the usage of a simple, stable and affordable wind machine that operates silently without even the blade tip noise that is usually produced by the traditional horizontal axis windmills. In addition, due to MAT’s visible structure, the migratory bird kills are projected to be minimal.

The wind augmenter and the wind diverter are the latest technologies used in the Hunter Project. The wind is funneled into the blade by the augmenter thus increasing the functional wind speed. The wind from the back side of the returning blade is diverted by the diffuser thus increasing the output and reducing drag.

Mass Megawatts will continue to be competitive with other wind technologies and also with fossil fuels that include natural gas and coal if the initial tests continue to have positive results. Mass Megawatts Wind Power possesses a market capitalization that amounts to less than $5 million.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.